Captozyme is a vertically integrated healthcare company with proprietary technologies focused on hyperoxaluria. Using sound scientific principles and expert knowledge, Captozyme is dedicated to advancing the standard of care. Whether creating our own pipeline of products or working with partners to advance the discovery of new opportunities we are committed to making a difference.
Oxalate stones represent 80% of all stones formed and are a major health care problem globally. Nearly 1 in every 10 people will experience a kidney stone in their lifetime and there are no satisfactory preventive treatments on the market to date. In fact, recurrent stone formers make up over 3 million people in the US alone. Captozyme is in position to quickly penetrate this market by way of launching its first medical food product through GRASE approval. The unmet need holds a market potential of annual global sales ranging from 1.2-20 billion USD.
Primary Hyperoxaluria (PH) is a rare genetic disorder that causes pain and debilitation from birth. There is currently no satisfactory treatment for this orphan disease, and most patients do not reach adulthood. The worldwide population include between 1000 to 4000 patients; thus, with an estimated population of at least 2000 patients in the US and EU, the corresponding market potential for this product is estimated to amount to over 400 million USD annually.
Contact Investor Relations
For investor inquiries, please email email@example.com or complete the form below.